Related references
Note: Only part of the references are listed.Iron starvation induces apoptosis in rhizopus oryzae in vitro
Fazal Shirazi et al.
VIRULENCE (2015)
CotH3 mediates fungal invasion of host cells during mucormycosis
Teclegiorgis Gebremariam et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Prospective antifungal therapy (PATH) alliance®: focus on mucormycosis
Dimitrios P. Kontoyiannis et al.
MYCOSES (2014)
Combination Therapy for Mucormycosis: Why, What, and How?
Brad Spellberg et al.
CLINICAL INFECTIOUS DISEASES (2012)
Pathogenesis of Mucormycosis
Ashraf S. Ibrahim et al.
CLINICAL INFECTIOUS DISEASES (2012)
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial
Brad Spellberg et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Risk factors for mortality in patients with mucormycosis
Brad Spellberg et al.
MEDICAL MYCOLOGY (2012)
Mucormycosis Caused by Unusual Mucormycetes, Non-Rhizopus, -Mucor, and -Lichtheimia Species
Marisa Z. R. Gomes et al.
CLINICAL MICROBIOLOGY REVIEWS (2011)
The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis
Ashraf S. Ibrahim et al.
MOLECULAR MICROBIOLOGY (2010)
Recent Advances in the Management of Mucormycosis: From Bench to Bedside
Brad Spellberg et al.
CLINICAL INFECTIOUS DISEASES (2009)
The iron chelator deferasirox protects mice from mucormycosis through iron starvation
Ashraf S. Ibrahim et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Novel perspectives on mucormycosis: Pathophysiology, presentation, and management
B Spellberg et al.
CLINICAL MICROBIOLOGY REVIEWS (2005)
Epidemiology and outcome of zygomycosis: A review of 929 reported cases
MM Roden et al.
CLINICAL INFECTIOUS DISEASES (2005)
Share Paper
